TY - JOUR

T1 - Intracoronary and systemic melatonin to patients with acute myocardial infarction

T2 - protocol for the IMPACT trial

AU - Halladin, Natalie L

AU - Busch, Sarah Ekeløf

AU - Jensen, Svend Eggert

AU - Hansen, Henrik Steen

AU - Zaremba, Tomas

AU - Aarøe, Jens

AU - Rosenberg, Jacob

AU - Gögenur, Ismail

PY - 2014/2

Y1 - 2014/2

N2 - INTRODUCTION: Ischaemia-reperfusion injury following acute myocardial infarctions (AMI) is an unavoidable consequence of the primary percutaneous coronary intervention (pPCI) procedure. A pivotal mechanism in ischaemia-reperfusion injury is the production of reactive oxygen species following reperfusion. The endogenous hormone, melatonin, works as an antioxidant and could potentially minimise the ischaemia-reperfusion injury. Given intracoronarily, it enables melatonin to work directly at the site of reperfusion. We wish to test if melatonin, as an antioxidant, can minimise the reperfusion injury following pPCI in patients with AMI.MATERIAL AND METHODS: The IMPACT trial is a multicentre, randomised, double-blinded, placebo-controlled study. We wish to include 2 × 20 patients with ST-elevation myocardial infarctions undergoing pPCI within six hours from symptom onset. The primary end-point is the Myocardial Salvage Index assessed by cardiovascular magnetic resonance imaging on day 4 (± 1) after pPCI. The secondary end-points are high-sensitivity troponin, creatinekinase myocardial band and clinical events.CONCLUSION: The aim of the IMPACT trial is to evaluate the effect of melatonin on reperfusion injuries following pPCI. Owing to its relatively non-toxic profile, melatonin is an easily implementable drug in the clinical setting, and melatonin has the potential to reduce morbidity in patients with AMI.FUNDING: This study received no financial support from the industry.TRIAL REGISTRATION: www.clinicaltrials.gov, clinical trials identifier: NCT01172171.

AB - INTRODUCTION: Ischaemia-reperfusion injury following acute myocardial infarctions (AMI) is an unavoidable consequence of the primary percutaneous coronary intervention (pPCI) procedure. A pivotal mechanism in ischaemia-reperfusion injury is the production of reactive oxygen species following reperfusion. The endogenous hormone, melatonin, works as an antioxidant and could potentially minimise the ischaemia-reperfusion injury. Given intracoronarily, it enables melatonin to work directly at the site of reperfusion. We wish to test if melatonin, as an antioxidant, can minimise the reperfusion injury following pPCI in patients with AMI.MATERIAL AND METHODS: The IMPACT trial is a multicentre, randomised, double-blinded, placebo-controlled study. We wish to include 2 × 20 patients with ST-elevation myocardial infarctions undergoing pPCI within six hours from symptom onset. The primary end-point is the Myocardial Salvage Index assessed by cardiovascular magnetic resonance imaging on day 4 (± 1) after pPCI. The secondary end-points are high-sensitivity troponin, creatinekinase myocardial band and clinical events.CONCLUSION: The aim of the IMPACT trial is to evaluate the effect of melatonin on reperfusion injuries following pPCI. Owing to its relatively non-toxic profile, melatonin is an easily implementable drug in the clinical setting, and melatonin has the potential to reduce morbidity in patients with AMI.FUNDING: This study received no financial support from the industry.TRIAL REGISTRATION: www.clinicaltrials.gov, clinical trials identifier: NCT01172171.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antioxidants

KW - Clinical Protocols

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Injections, Intravenous

KW - Male

KW - Melatonin

KW - Middle Aged

KW - Myocardial Infarction

KW - Percutaneous Coronary Intervention

KW - Reperfusion Injury

KW - Research Design

KW - Treatment Outcome

KW - Young Adult

M3 - Journal article

C2 - 24495883

VL - 61

JO - Danish Medical Journal

JF - Danish Medical Journal

SN - 2245-1919

IS - 2

M1 - A4773

ER -